| Literature DB >> 26109736 |
Nienke M ter Haar1, Marlen Oswald2, Jerold Jeyaratnam3, Jordi Anton4, Karyl S Barron5, Paul A Brogan6, Luca Cantarini7, Caroline Galeotti8, Gilles Grateau9, Veronique Hentgen10, Michael Hofer11, Tilmann Kallinich12, Isabelle Kone-Paut13, Helen J Lachmann14, Huri Ozdogan15, Seza Ozen16, Ricardo Russo17, Anna Simon18, Yosef Uziel19, Carine Wouters20, Brian M Feldman21, Sebastiaan J Vastert22, Nico M Wulffraat22, Susanne M Benseler23, Joost Frenkel3, Marco Gattorno24, Jasmin B Kuemmerle-Deschner2.
Abstract
: Autoinflammatory diseases are characterised by fever and systemic inflammation, with potentially serious complications. Owing to the rarity of these diseases, evidence-based guidelines are lacking. In 2012, the European project Single Hub and Access point for paediatric Rheumatology in Europe (SHARE) was launched to optimise and disseminate regimens for the management of children and young adults with rheumatic diseases, facilitating the clinical practice of paediatricians and (paediatric) rheumatologists. One of the aims of SHARE was to provide evidence-based recommendations for the management of the autoinflammatory diseases cryopyrin-associated periodic syndromes (CAPS), tumour necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS) and mevalonate kinase deficiency (MKD). These recommendations were developed using the European League Against Rheumatism standard operating procedure. An expert committee of paediatric and adult rheumatologists was convened. Recommendations derived from the systematic literature review were evaluated by an online survey and subsequently discussed at a consensus meeting using Nominal Group Technique. Recommendations were accepted if more than 80% agreement was reached. In total, four overarching principles, 20 recommendations on therapy and 14 recommendations on monitoring were accepted with ≥80% agreement among the experts. Topics included (but were not limited to) validated disease activity scores, therapy and items to assess in monitoring of a patient. By developing these recommendations, we aim to optimise the management of patients with CAPS, TRAPS and MKD. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.Entities:
Keywords: Fever Syndromes; Multidisciplinary team-care; Treatment
Mesh:
Year: 2015 PMID: 26109736 DOI: 10.1136/annrheumdis-2015-207546
Source DB: PubMed Journal: Ann Rheum Dis ISSN: 0003-4967 Impact factor: 19.103